Caris Life Sciences, Inc.

Caris sells primarily into the clinical oncology market, where physicians and cancer centers order profiling tests to help choose therapies and monitor disease. The company specifically notes that a large share of its top customers by case volume are academic medical centers and corporate physician practices, with a strong focus on the community setting where most cancer patients are treated. It also serves biopharma companies through a dedicated business development team that sells research and data services supported by its molecular datasets. Adoption depends on physicians, hospital systems, and payers accepting the clinical utility and reimbursement of its tests, so customer demand is tied closely to evidence generation and coverage decisions.

Caris is trying to extend its core molecular profiling franchise by increasing adoption of MI Profile and Caris Assure while monetizing the launch of MI Cancer Seek. A major strategic priority is to prove clinical utility through validation studies, clinical trials, and peer-reviewed evidence so that payers, physicians, and institutions continue to expand coverage and usage. The company is also investing in new applications such as early detection, MRD tracking, and treatment monitoring through Caris Detect, which could broaden its addressable market beyond current therapy-selection use cases. In parallel, Caris is building its biopharma business around its clinico-genomic datasets and scientific credibility, using a specialized business development team to win data and research partnerships.